JP2003315332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003315332A5 JP2003315332A5 JP2002109165A JP2002109165A JP2003315332A5 JP 2003315332 A5 JP2003315332 A5 JP 2003315332A5 JP 2002109165 A JP2002109165 A JP 2002109165A JP 2002109165 A JP2002109165 A JP 2002109165A JP 2003315332 A5 JP2003315332 A5 JP 2003315332A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- amino acid
- acid sequence
- seq
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 31
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 21
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 21
- 238000000034 method Methods 0.000 claims 17
- 102000005962 receptors Human genes 0.000 claims 16
- 108020003175 receptors Proteins 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 10
- 108091033319 polynucleotide Proteins 0.000 claims 9
- 239000002157 polynucleotide Substances 0.000 claims 9
- 102000040430 polynucleotide Human genes 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 238000006243 chemical reaction Methods 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 208000015181 infectious disease Diseases 0.000 claims 7
- 208000027866 inflammatory disease Diseases 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 238000002054 transplantation Methods 0.000 claims 7
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims 6
- 230000000521 hyperimmunizing effect Effects 0.000 claims 6
- 238000012216 screening Methods 0.000 claims 6
- 230000004060 metabolic process Effects 0.000 claims 5
- 239000013612 plasmid Substances 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 4
- 108091027981 Response element Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000007813 immunodeficiency Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 210000004102 animal cell Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 3
- 229940039227 diagnostic agent Drugs 0.000 claims 3
- 208000020694 gallbladder disease Diseases 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 230000003449 preventive effect Effects 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102000034353 G alpha subunit Human genes 0.000 claims 1
- 108091006099 G alpha subunit Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 108060001084 Luciferase Proteins 0.000 claims 1
- 239000005089 Luciferase Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002109165A JP4184697B2 (ja) | 2001-04-12 | 2002-04-11 | スクリーニング方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-114203 | 2001-04-12 | ||
| JP2001114203 | 2001-04-12 | ||
| JP2001180562 | 2001-06-14 | ||
| JP2001-180562 | 2001-06-14 | ||
| JP2001214922 | 2001-07-16 | ||
| JP2001-214922 | 2001-07-16 | ||
| JP2001397767 | 2001-12-27 | ||
| JP2001-397767 | 2001-12-27 | ||
| JP2002045728 | 2002-02-22 | ||
| JP2002-45728 | 2002-02-22 | ||
| JP2002109165A JP4184697B2 (ja) | 2001-04-12 | 2002-04-11 | スクリーニング方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003315332A JP2003315332A (ja) | 2003-11-06 |
| JP2003315332A5 true JP2003315332A5 (https=) | 2005-08-18 |
| JP4184697B2 JP4184697B2 (ja) | 2008-11-19 |
Family
ID=29554554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002109165A Expired - Fee Related JP4184697B2 (ja) | 2001-04-12 | 2002-04-11 | スクリーニング方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4184697B2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005081663A (ja) | 2003-09-08 | 2005-03-31 | Nissan Motor Co Ltd | 樹脂製チューブ及び燃料系配管用チューブ |
| AU2005248722A1 (en) * | 2004-04-13 | 2005-12-08 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders |
| JP5378469B2 (ja) | 2011-08-11 | 2013-12-25 | 学校法人 日本歯科大学 | 医療用薬剤 |
-
2002
- 2002-04-11 JP JP2002109165A patent/JP4184697B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113117074B (zh) | 用于治疗海帕西啶介导的病症的方法 | |
| Matsumoto et al. | Functional analysis of titin/connectin N2-B mutations found in cardiomyopathy | |
| TW200912000A (en) | Inhibitors of the binding between HDM2 and the proteasome | |
| CN101852804B (zh) | Gdf15蛋白的抗体的新用途 | |
| ES2625316T3 (es) | Neuquinasa, una proteína corriente abajo de neuregulina | |
| JP2021531038A5 (https=) | ||
| JP2005528083A5 (https=) | ||
| JP2005528086A5 (https=) | ||
| JP2008502355A5 (https=) | ||
| JP2003506042A (ja) | セクレチン様ファミリーの新規ｇｐｃｒ様分子１５５７１及びその使用 | |
| JP2003315332A5 (https=) | ||
| Alten et al. | Prevention of hypovolemic circulatory collapse by IL-6 activated Stat3 | |
| JP6833037B2 (ja) | 脂肪肝の診断または治療のためのロイシンジッパータンパク質の用途 | |
| Nardelli et al. | Osteostat/tumor necrosis factor superfamily 18 inhibits osteoclastogenesis and is selectively expressed by vascular endothelial cells | |
| JP2005528080A5 (https=) | ||
| US20070117138A1 (en) | Splice variant cannabinoid receptor (cb1b) | |
| ES2318910T3 (es) | Nuevo factor de transcripcion de genes mhc de clase ii; sustancias capaces de inhibir este nuevo factor de transcripcion y usos medicos de estas sustancias. | |
| JP2016520570A (ja) | Ａ型インフルエンザウイルス感染の治療又は予防に使用するためのｐａｒ−４アンタゴニスト | |
| US20250326795A1 (en) | Use of d-enantiomeric peptide ligands of monomeric tau for the therapy of various tauopathies | |
| JP2008509659A5 (https=) | ||
| TW200540184A (en) | CD7 as biomarker and therapeutic target for psoriasis | |
| CN109414504B (zh) | 药物组合物或食品组合物及评价活性成分体内效果的方法 | |
| JP2007505825A5 (https=) | ||
| Szuchet et al. | Oligodendrocytes express an α/β‐interferon‐susceptible Mx gene: Molecular characterization of the encoded protein | |
| Dinh et al. | An NKX-COUP-TFII genomic code for mucosal vascular addressins and organ morphogenesis |